Maricann Group Inc. Receives Their GMP Certification with the European Medicines Agency

Maricann Group Inc. (CSE:MARI)(OTCQB:MRRCF) announced this morning that the company has received its Good Manufacturing Practice (GMP) certification from the European Medicines Agency.

The Maricann Group is a vertically integrated, public cannabis company located in Ontario, Canada. The company currently operates cultivation, extraction, formulation and distribution facilities in accordance with federal law in Canada.

The company started the difficult process of obtaining their GMP certification back in the Q4 of 2017. Health inspectors visited the Maricann Group’s facility in Langton, Ontario where the company is currently expanding their operations to house 942,000 sq. ft. of production and processing space.

Maricann is one of only 6 different medical marijuana producers in Canada that’s have obtained their GMP certification. By obtaining this, the Maricann Group qualifies to now export medicinal cannabis onto the continent of Europe.

Ben Ward, CEO of the company, gave this statement in the press release:

“EMA-GMP certification of our cultivation facility in Canada demonstrates further progress at Maricann. External validation of our operations provides comfort to our patients and consumers that we exceed industry standards. Our commitment to total quality, from origination to finished product is now certified.”

Leave a Comment